Huntingdon and Harlan move forward under a new moniker

Envigo CEO Brian Cass

Huntingdon Life Sciences, a year removed from acquiring Harlan Laboratories, is changing the combined company's name to Envigo as it works to expand its presence on the CRO market.

The company, specializing in nonclinical research, now employs about 3,800 people and brings in nearly $500 million a year in revenue, according to management.

Huntingdon, which makes its money running animal studies for the pharma, crop protection and chemical industries, merged with Harlan in 2014 to expand its reach into biotech and med tech. Now, moving forward as Envigo, the company is looking to raise its profile in the fields of research models and preclinical studies, CEO Brian Cass said.

"We at Envigo will be united with our customers in the knowledge that the research they conduct, and the products we help them develop, have the potential to enhance life," Cass said in a statement. "Our new name and brand will reflect our integrated management structure and the broader product and service offerings of our combined organization."

The company touts itself as the world's largest provider of research services to the crop protection and chemical industries, the second largest player in animal models and the third largest CRO focused on preclinical pharma studies.

- read the statement

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.